The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Open accessAbstract
Background: Evaluation of cardiovascular prognosis in patients with stable coronary heart disease is based on clinical characteristics and biomarkers indicating dysglycemia, dyslipidemia, renal dysfunction, and possibly cardiac dysfunction. Inflammation plays a key role in atherosclerosis, but the association between inflammatory biomarkers and clinical outcomes is less studied in this population. Methods and Results: Overall, 15 828 patients with coronary heart disease in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial were randomized to treatment with darapladib or placebo and observed for a median of 3.7 years. In 14 611 patients, levels of interleukin‐6 ( IL ‐6) and high‐sensitivity C‐reactive protein were measured in plasma samples: median levels were 2.1 (interquartile range, 1.4–3.2) ng/L and 1.3 (interquartile range, 0.6–3.1) mg/L, respectively. Associations between continuous levels or quartile groups and adjudicated outcomes were evaluated by spline graphs and Cox regression adjusted for clinical factors and cardiovascular biomarkers. IL ‐6 was associated with increased risk of major adverse cardiovascular events (quartile 4 versus quartile 1 hazard ratio [ HR ], 1.60; 95% confidence interval [CI], 1.30–1.97; P <0.0001); cardiovascular death ( HR , 2.15; 95% CI, 1.53–3.04; P <0.0001); myocardial infarction ( HR , 1.53; 95% CI, 1.14–2.04; P <0.05); all‐cause mortality ( HR , 2.11; 95% CI, 1.62–2.76; P <0.0001); and risk of hospitalization for heart failure ( HR , 2.28; 95% CI, 1.34–3.89; P <0.001). Cancer death was doubled in the highest IL ‐6 quartile group ( HR , 2.34; 95% CI, 1.20–4.53; P <0.05). High‐sensitivity C‐reactive protein was associated with both cardiovascular and non‐cardiovascular events in the unadjusted model, but these did not remain after multivariable adjustments. Conclusions: IL ‐6, an upstream inflammatory marker, was independently associated with the risk of major adverse cardiovascular events, cardiovascular and all‐cause mortality, myocardial infarction, heart failure, and cancer mortality in patients with stable coronary heart disease. IL‐6 might reflect a pathophysiological process involved in the development of these events. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00799903.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Production of C-reactive protein and risk of coronary events in stable and unstable angina
Haverkate, E., Thompson, S. G., Pyke, S. D., Gallimore, J. R., & Group, M. B. P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07591-5 · Cited by 1,500
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
Kaptoge, S., Seshasai, S. R. K., Gao, P., Freitag, D. F., Butterworth, A. S., Borglykke, A., Di Angelantonio, E., Gudnason, V., Rumley, A., Lowe, G. D. O., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht367 · Cited by 666
Biasucci, L. M., Liuzzo, G., Grillo, R. L., Caligiuri, G., Rebuzzi, A. G., Buffon, A., Summaria, F., Ginnetti, F., Fadda, G., & Maseri, A. (1999) · Circulation · doi:10.1161/01.cir.99.7.855 · Cited by 582
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579 · cited 2×
“The event definitions and main results of the study have been presented elsewhere.(10)”
BackgroundAnti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Hartman, J., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000021 · Cited by 375
The varying faces of IL-6: From cardiac protection to cardiac failure
Fontes, J. A., Rose, N. R., & Čiháková, D. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.024 · Cited by 337
C-reactive protein is a mediator of cardiovascular disease
Bisoendial, R. J., Boekholdt, S. M., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq238 · Cited by 232
White, H. D., Held, C., Stewart, R., Watson, D. I., Harrington, R. A., Budaj, A., Steg, P. G., Cannon, C. P., Krug‐Gourley, S., Wittes, J. T., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.006 · Cited by 125
Self-citationBro‐Jeppesen, J., Kjærgaard, J., Stammet, P., Wise, M. P., Hovdenes, J., Åneman, A., Horn, J., Devaux, Y., Erlinge, D., Gasche, Y., et al. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.10.009 · Cited by 108
Hijazi, Z., Aulin, J., Andersson, U., Alexander, J. H., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., Hylek, E. M., Lópes, R. D., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308887 · Cited by 105
Self-citationOptimizing Clinical Use of Biomarkers in High-Risk Acute Heart Failure Patients
Demissei, B. G., Valente, M. A. E., Cleland, J. G. F., O’Connor, C. M., Metra, M., Ponikowski, P. P., Teerlink, J. R., Cotter, G., Davison, B. A., Givertz, M. M., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.443 · Cited by 82
Spoto, B., Mattace-Raso, F. U. S., Sijbrands, E. J. G., Leonardis, D., Testa, A., Pisano, A., Pizzini, P., Cutrupi, S., Parlongo, R. M., D’Arrigo, G., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07000714 · Cited by 77
White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin
Stewart, R., White, H. D., Kirby, A. C., Heritier, S. R., Simes, R. J., Nestel, P. J., West, M., Colquhoun, D. M., & Tonkin, A. M. (2005) · Circulation · doi:10.1161/01.cir.0000160924.73417.26 · Cited by 65
Self-citationRisk prediction in stable angina pectoris
Kahan, T., Forslund, L., Held, C., Björkander, I., Billing, E., Eriksson, S. V., Näsman, P., Rehnqvist, N., & Hjemdahl, P. (2012) · European Journal of Clinical Investigation · doi:10.1111/eci.12025 · Cited by 9
Self-citation
Cited by
Research Progress on the Relationship between Atherosclerosis and Inflammation
Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., & Chen, R. (2018) · Biomolecules · doi:10.3390/biom8030080 · Cited by 872
Ridker, P. M., Devalaraja, M., Baeres, F. M. M., Engelmann, M. D. M., Hovingh, G. K., Ivkovic, M., Lo, L., Kling, D., Pergola, P., Raj, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00520-1 · Cited by 737
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Medina-Leyte, D. J., Zepeda-García, O., Domínguez-Pérez, M., González-Garrido, A., Villarreal-Molina, T., & Jacobo-Albavera, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083850 · Cited by 623
Metadata
- Authors
- Held, C., White, H. D., Stewart, R. A. H., Budaj, A., Cannon, C. P., Hochman, J. S., Koenig, W., Siegbahn, A., Steg, P. G., Soffer, J., Weaver, W. D., Östlund, O., Wallentin, L., & on behalf of the STABILITY Investigators
- Venue
- Journal of the American Heart Association
- Published
- 2017-10-11
- Volume
- 6
- Issue
- 10
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2765664486
- Cited by
- 291
- References
- 22
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.